Clinical trial

Consolidative Stereotactic Radiotherapy for Oligo-Residual Advanced EGFR-Mutant NSCLC After First-Line Third-Generation EGFR-TKI Plus Chemotherapy

NCT07822984

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2026-10-01

PhasePHASE2

Study timeline

Study start (estimated)2026-10-01Date precision: month

Registry last updated2026-09-16

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

EGFR-mutant Non-small Cell Lung Cancerunresolved

SBRTunresolved

NSCLC (Advanced Non-small Cell Lung Cancer)unresolved

Interventions

Third-generation EGFR tyrosine kinase inhibitorDRUG

Platinum plus pemetrexed chemotherapyDRUG

Pemetrexed maintenance therapyDRUG

Consolidative stereotactic radiotherapyRADIATION

Sponsors & collaborators

Fudan Universitylead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07822984 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.